Previous Close | 4.0900 |
Open | 4.0600 |
Bid | 3.9800 x 1800 |
Ask | 4.0600 x 2900 |
Day's Range | 4.0150 - 4.1500 |
52 Week Range | 1.8200 - 5.9500 |
Volume | 1,862,986 |
Avg. Volume | 2,884,093 |
Market Cap | 760.596M |
Beta (5Y Monthly) | 1.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0930 |
Earnings Date | Oct 29, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.00 |
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer. “We welcome Andy Hurley as we transition into a commercial stage company with a robust research and clinical pipeline,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Andy’s experience and passion in successfully commercializing biopharmaceutical agents and his excitement about our portfolio made him a natural fit to join our team.” "I am excited to join Agenus, one of the true pioneers in immuno-oncology, to lead the efforts for its first potential commercial product launch and to help determine the optimal commercial path for Agenus’ vast and differentiated pipeline,” said Andy Hurley, Chief Commercial Officer at Agenus. “I am excited about the potential of balstilimab alone and in combination with Agenus’ other novel candidates, like AGEN1181, to bring potentially life-altering therapies to patients.” Andy brings to Agenus three decades of international experience as a strategic commercial leader at large and small biopharmaceutical companies. He joins Agenus from his most recent role as the Senior Vice President at Syneos Health. Before Syneos Health, he was Chief Commercial Officer at Ocular Therapeutix where he was hired to pivot the organization from an R&D company to a fully integrated commercial company. Andy also held executive leadership roles at Sunovion, Dyax, and Forest Pharmaceuticals. He holds a Bachelor of Science in Consumer Studies from the University of Vermont. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding commercialization and the anticipated commercial launch of Agenus’ candidates, as well as their therapeutic potential. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact:Agenus Inc. Caroline Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com
Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will host its inaugural Agenus Insights on “Optimally Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m. ET. This R&D miniseries, a brief yet concise summary of key insights into the most impactful areas of research in immuno-oncology and Agenus’ contributions to them, will include a 15-minute presentation and a 15-minute Q&A session. S1E1, “Optimally Targeting TIGIT,” will be hosted by Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery. The webinar will begin with a fast-paced discussion by Dr. Steven O’Day and Dr. Dhan Chan highlighting the clinical validation of TIGIT as an anti-cancer target and the rationale for Agenus’ Fc-enhanced design. The remainder of the webinar will be made available for a Q&A session. Registration for the webinar can be done in advance at https://agenusbio.zoom.us/webinar/register/WN_tOrL5VCkRoSh7lFKqOCKAA. A replay will be available after the webinar on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding TIGIT. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact:Agenus Inc. Caroline Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com
6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancersNo complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its Phase 1/2 trial of AGEN1181, its next-generation anti-CTLA-4, as monotherapy and in combination with Agenus’ anti-PD-1 balstilimab. “These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody. AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab,” said Dr. Steven O’Day, Chief Medical Officer at Agenus. “The responses seen in patients with ovarian and MSS colorectal cancer are particularly encouraging given the generally low activity seen with immunotherapy in these indications.” The Phase 1 dose escalation trial has had no reports of complement-mediated toxicities. These are severe toxicities associated with first-generation CTLA-4 antibodies. The trial has also defined the optimal combination dose for AGEN1181 +/- balstilimab. Agenus also presented on the first-ever report of intratumoral Treg depletion with a CTLA-4 antibody in clinical trials at SITC 2020. The summary of responses with AGEN1181 alone or in combination with balstilimab are as follows:1 CR in PD-L1(-) MSS endometrial cancer patient (1181 monotherapy)CR by PET in PD-L1(-) MSS endometrial cancer patient (1181 + bal)PR in PD-L1(-) refractory ovarian cancer patient (1181 + bal)PR in colorectal cancer patient (1181 + bal)PR in MSS colorectal cancer patient (1181 + bal) – new confirmed responsePR in ovarian cancer patient (1181 + bal) – new confirmed response AGEN1181 alone and in combination with balstilimab has expanded dosing into colorectal cancer. Phase 2 trials in additional cancer indications are scheduled to commence shortly. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody and the planned initiation of Phase 2 trials in additional cancer indications. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Contact:Agenus Inc. Caroline Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com _________________1 Response evaluation criteria in solid tumors (RECIST v1.1)